Duke Energy Corp vs ResMed Inc. — how do they compare? Duke Energy Corp trades at $116.63 (market cap $91.10B), while ResMed Inc. trades at $230.22 (market cap $31.89B). The key difference: Duke Energy Corp is far larger — about 2.9× ResMed Inc.'s market cap, and Duke Energy Corp pays the higher dividend (3.71%). Which is the better fit depends on your goals — on Pluang, investors hold Duke Energy Corp for 74 Days and ResMed Inc. for 51 Days on average.
| DUK | RMD | |
|---|---|---|
Market Cap | $91.10B | $31.89B |
Volume | 4,199,050 | 618,314 |
Sector | Utilities | Health |
52-Week High | $133.46 | $277.88 |
52-Week Low | $113.23 | $182.82 |
Typical Hold Time | 74 Days | 51 Days |
Enterprise Value | $183.61B | $31.24B |
Dividend Yield | 3.71% | 1.16% |
Signals from Pluang's Aura AI — not financial advice
Duke Energy (DUK) trades at $116.55, up 0.91% today, with a bullish technical signal despite mixed moving averages. The company shows consistent earnings beats, with Q2 2026 EPS of $1.43 exceeding the $1.30 estimate. Revenue grew to $32.24B in 2025, and net income margin improved to 15.78%. Recent news highlights dividend declarations and data center growth opportunities, though rising Treasury yields pose a headwind for utility stocks.
DUK offers a stable dividend and benefits from data center demand, but high debt levels and interest rate sensitivity present risks. Analyst consensus is a Buy with a $134.44 price target, implying 15% upside. The stock's valuation is reasonable with a P/E of 17.6, supporting a cautious bullish outlook amid macroeconomic pressures.
ResMed (RMD) trades at $228.37, up 1.06% today, with a bullish technical signal and strong fundamentals. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Revenue grew to $5.15B in 2025, with a robust net income margin of 26.94%. Recent news highlights management's presentation at the Morgan Stanley Healthcare Conference and an upcoming Q1 2027 earnings report.
The outlook is positive, supported by earnings growth targets of 12-14% and a consensus price target of $242.70. Key risks include competitive pressures and ongoing legal investigations. Institutional buying activity and analyst upgrades reflect confidence, but investors should monitor execution against growth targets and any developments from the legal probe.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Duke Energy is one of the largest U.S. utilities, with regulated utilities in the Carolinas, Indiana, Florida, Ohio, and Kentucky that deliver electricity to nearly 8 million customers. Its natural gas utilities serve more than 1.5 million customers. Duke operates in three major segments: electric utilities and infrastructure
Read more on DUK →ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →